Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …

The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …

The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases
and is widely used either as monotherapy or in combination strategies. It has produced …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

BCL-2 family proteins regulate the intrinsic pathway of programmed cell death (apoptosis)
and play a key role in the development and health of multicellular organisms. The dynamics …

BH3-mimetic drugs are an anti-cancer therapy that can induce apoptosis in malignant cells
by directly binding and inhibiting pro-survival proteins of the BCL-2 family. The BH3-mimetic …

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic
machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Disruption of the physiologic balance between cell proliferation and cell death is an
important step of cancer development. Increased resistance to apoptosis is a key oncogenic …